Verition Fund Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q4
– Sell
-14,228
Closed -$740K – 375
2014
Q3
$740K Buy
14,228
+3,756
+36% +$182K 0.1% 154
2014
Q2
$486K Sell
10,472
-23,644
-69% -$933K 0.05% 266
2014
Q1
$1.36M Buy
+34,116
New +$1.55M 0.21% 79

Other funds holding BIB

Verition Fund Management's BIB Position: Q4 2014 in Review

Verition Fund Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2014, closing a stake of 14,228 shares — an estimated $740K sold.

Verition Fund Management first reported a position in BIB in Q1 2014 and held it in 3 quarters. The position peaked at $1.36M in Q1 2014. 29 funds tracked by Wall St. Rank hold BIB as of Q4 2014.

  • Verition Fund Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Verition Fund Management sold 14,228 ProShares Ultra NASDAQ Biotechnology shares in Q4 2014, an estimated $740K.
  • Verition Fund Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 3 quarters.
  • Verition Fund Management's ProShares Ultra NASDAQ Biotechnology position peaked at $1.36M in Q1 2014.
  • 29 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2014.

Based on Verition Fund Management's 13F filing for Q4 2014, filed 13 Feb 2015.